Atorvastatin treatment meets new European recommendations for the treatment of dyslipidemias.

Kardiovaskularne bolesti (KVB) su i dalje vodeći uzrok globalnog mortaliteta te uzrokuju gotovo polovicu smrti u Europi. Istraživanja pokazuju da dislipidemija predstavlja jedan od najznačajnijih čimbenika rizika koji doprinose razvoju KVB. U kolovozu 2011. god. Europsko kardiološko društvo i Europsko društvo za aterosklerozu objavili su nove smjernice za liječenje pacijenata s dislipidemijama, koje snižene razine LDL kolesterola i dalje smatraju primarnim ciljem liječenja. Smjernice preporučaju propisivanje terapije statinima do najviše moguće doze ili najviše podnošljive doze kako bi se dosegla ciljna razina LDL kolesterola. Nekoliko kliničkih studija potvrdilo je učinkovitost i sigurnost atorvastatina u kliničkoj praksi kod širokog spektra bolesnika. Studija Anglo Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA) je ukazala da smanjenje velikih kardiovaskularnih događaja primjenom atorvastatina može omogućiti dugoročnu dobrobit na ukupnu smrtnost. Krka je posvećena kontinuiranoj procjeni učinkovitosti i sigurnosti svojih proizvoda.Cardiovascular disease (CVD) still remains the leading cause of global mortality and causes nearly half of all deaths in Europe. Research shows that among many risk factors contributing to the development of CVD, dyslipidemia is one of the most significant. In August 2011, the European Society of Cardiology and the European Atherosclerosis Society released new guidelines for the management of patients with dyslipidemias, which consider low LDL cholesterol levels still as the primary treatment target. The guidelines recommend physicians prescribe statin therapy up to the highest dose possible or the highest tolerable dose to reach the target LDL cholesterol level. Several clinical studies confirmed the efficacy and safety of atorvastatin in clinical practice in a wide range of patients. The Anglo Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA) has demonstrated that reductions in major cardiovascular events with atorvastatin may contribute to long-term benefits on all-cause mortality. Krka is dedicated to continuously evaluate the efficacy and safety of its products